Accordingly, Cby1 reduced expression in CD34+ cells of CML-CP patients and HP was associated with a significant increment of nuclear beta catenin and enhanced transcription of cyclin D1, a Wnt/beta catenin target gene involved in the maintenance of CD34+ pool (p<0.05 or less) [28]. The gene discussed is CBY1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.